Rotork is ensuring the pillars are in place to deliver growth. The H118 report demonstrated end-market support, with order book growth across all divisions and solid operating performance. Management now has both the framework and the personnel in place to drive the initiatives on route to market, new product development and lean manufacturing.
Written by
Rotork |
Preparing for acceleration
|
Industrial engineering |
QuickView
8 August 2018 |
Share price graph
Share details
Business description
Bull
Bear
Analysts
Rotork is a client of Edison Investment Research Limited |
||||||||||||||||||||||||||
Rotork is ensuring the pillars are in place to deliver growth. The H118 report demonstrated end-market support, with order book growth across all divisions and solid operating performance. Management now has both the framework and the personnel in place to drive the initiatives on route to market, new product development and lean manufacturing.
H118 report: Growth across all divisions
Rotork noted a positive market outlook and 13.3% y-o-y order growth on an organic constant currency basis. H118 reported revenue of £331.0m (H117 £299.7m) was up 14.8% on an organic constant currency with all divisions delivering growth and bringing book to bill to 1.1x. H118 adjusted operating profit also benefited from growth in all four divisions, at £65.4m (H117 £54.4m) up 25.1%. H117 adjusted EPS of 5.6p (H117 4.4p) was up 32.3% and the interim dividend of 2.20p (H117 2.05p) was up 7.3%. Full-year guidance has been maintained, with high single-digit revenue growth on a reported basis with c 300bp of headwind from currency. Adjusted operating margins are expected to be slightly ahead of FY17 (20.3%).
Sand, pebbles, boulders: Strategic initiatives
CEO Kevin Hostetler provided a strategy update and outlined key initiatives to be taken. These are classified by complexity and time to implement, from quicker and easier ‘sand’ initiatives to larger and more complex ‘boulders’. The group needs to build on its brand strength and technology recognition and be able to deliver improvements in turnaround times, on-time delivery and client communications. Altering the current sales force structure from the divisional structure aligned to products to one aligned with end markets will improve the ability of the sales teams and offer a broader range of products to the customers they visit. Meanwhile, the company continues to focus on the aftermarket opportunity, taking a more proactive rather than reactive role through the use of usage data. For new product development, the company is aiming to work smarter with the current budgeted spend within a framework that analyses ongoing and new opportunities.
Valuation: A valuable proposition
Rotork’s goal is to deliver the investment in the business through the savings generated over a two-year period. The balance sheet is strong, with net debt/EBITDA under 0.1x at the H118 report, and future M&A remains a possibility. However, the company should leverage end-market growth trends, while the shorter-term growth initiatives start to bear fruit.
|
Consensus estimates
Source: Bloomberg |
|
Disclaimer
|
|
Disclaimer
|
Research: Healthcare
RedHill reported top-line results from its Phase III trial with RHB-104 in Crohn’s Disease (CD). The primary endpoint was met with 37% of patients in the active arm achieving remission at week 26 compared to 23% in placebo (p=0.013). Several other key secondary endpoints also demonstrated efficacy but, judging from the share price volatility on the day of the announcement and various comments in the public space, a lot of attention was paid to the secondary endpoint dealing with isolated late induction of remission at week 52, which introduced confusion, in our view. The initial share price reaction was positive with a >60% gain, but retracted, closing down 7.2%. We note that RedHill’s share price is up by more than 40% versus the current price since May 2018 and given that the RHB-104 data readout was the single biggest catalyst in mid-2018, we believe the share price appreciation over the last few months reflects the value added by RHB-104. Our new valuation is $423m or $19.8/ADS.